Rituxan (rituximab) - Roche
Pauci-Immune Crescentic Glomerulonephritis with Diffuse Alveolar Hemorrhage and Serologic Overlap: Navigating Myeloperoxidase (MPO)-ANCA Vasculitis with Concurrent Antinuclear Antibody (ANA) and Anti-Sjogren Syndrome-Related Antigen A (Anti-SSA) Positivity (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0793; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Second, although PEXIVAS showed no overall mortality benefit of plasma exchange in severe AAV, subgroup analyses suggested possible benefit in DAH. Rapid pulmonary improvement likely reflected glucocorticoid and plasmaphersis effect, whereas sustained serologic remission reflected rituximab-mediated B-cell depletion suggesting potential for continued renal recovery over 6-12 months." 
Acute Kidney Injury • ANCA Vasculitis • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Lupus Nephritis • Nephrology • Pulmonary Disease • Renal Disease • Sjogren's Syndrome • Vasculitis • MPO
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4557672
 
Jaleel Jerry Sweis; Austin L. Carey; Trent E. Rich; Xueguang (Gary) Chen
 
Oct 2, 2026
 
Prev Next